Kuru Göz Tedavisi İçin İlaç Taşıyıcı Sistemler
Referanslar
Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Deutsches Ärzteblatt International. 2015;112(5):71. doi: 10.3238/arztebl.2015.0071
Alshamrani, A. A., Almousa, A. S., Almulhim, A. A., et al. Prevalence and risk factors of dry eye symptoms in a Saudi Arabian population. Middle East African Journal Of Ophthalmology.2017;24(2):67.doi: 10.4103/meajo.MEAJO_281_16
Johnson ME, Murphy PJ. Changes in the tear film and ocular surface from dry eye syndrome. Progress in retinal and eye research. 2004;23(4):449-74.doi: 10.1016/j.preteyeres.2004.04.003
Foulks GN, Nichols KK, Bron AJ, et al. Improving awareness, identification, and management of meibomian gland dysfunction. Ophthalmology. 2012;119(10):S1-S12.doi: 10.1016/j.ophtha.2012.06.064
Fujita M, Igarashi T, Kurai T, et al. Correlation between dry eye and rheumatoid arthritis activity. American Journal Of Ophthalmology. 2005;140(5):808-13.doi: 10.1016/j.ajo.2005.05.025
Niederkorn JY. Regulatory T cells and the eye. Immune Response and The Eye. 2007;92:131-9.doi: 10.1159/000099263
Ohashi Y, Ishida R, Kojima T, et al. Abnormal protein profiles in tears with dry eye syndrome. American Journal Of Ophthalmology. 2003;136(2):291-9.doi: 10.1016/S0002-9394(03)00203-4
Şimşek, C, Doğru, M, Kojima, T, et al. Current management and treatment of dry eye disease. Turkish Journal Of Ophthalmology,2018; 48(6):309. doi: 10.4274/tjo.69320
Berdy GJ, Abelson MB, Smith LM, et al. Preservative-free artificial tear preparations: assessment of corneal epithelial toxic effects. Archives of Ophthalmology. 1992;110(4):528-32. doi:10.1001/archopht.1992.01080160106043
Saettone MF, Monti D, TORRACCA MT, et al. Mucoadhesive ophthalmic vehicles: evaluation of polymeric low-viscosity formulations. Journal of Ocular Pharmacology and Therapeutics. 1994;10(1):83-92.doi: 10.1089/jop.1994.10.83
Avramoff A, Khan W, Ezra A, et al. Cyclosporin pro-dispersion liposphere formulation. Journal Of Controlled Release. 2012;160(2):401-6.doi: 10.1016/j.jconrel.2011.12.016
Perry HD, Solomon R, Donnenfeld ED, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Archives of Ophthalmology. 2008;126(8):1046-50. doi:10.1001/archopht.126.8.1046
Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000;47(2-3):119-25.doi:10.1016/s0162-3109(00)00192-2
Abidi A, Shukla P, Ahmad A. Lifitegrast: a novel drug for treatment of dry eye disease. Journal of Pharmacology and Pharmacotherapeutics. 2016;7(4):194-8.doi: 10.4103/0976-500X.195920
Korenfeld M, Nichols KK, Goldberg D, et al. Safety of KPI-121 ophthalmic suspension 0.25% in patients with dry eye disease: a pooled analysis of 4 multicenter, randomized, vehicle-controlled studies. Cornea. 2021;40(5):564-70. doi: 10.1097/ICO.0000000000002452
Foulks GN. Pharmacological management of dry eye in the elderly patient. Drugs & aging. 2008;25(2):105-18.doi: 10.2165/00002512-200825020-00003
Shichijo Y, Murakami T, Nakamura M. Stimulatory effect of diquafosol tetrasodium on tear fluid secretion in normal rabbits. Investigative Ophthalmology & Visual Science.2011; 52(14): 3766-3766.
Nakamura M, Imanaka T, Sakamoto A. Diquafosol ophthalmic solution for dry eye treatment. Advances in Therapy. 2012;29(7):579-89.doi: 10.1007/s12325-012-0033-9
Kinoshita S, Oshiden K, Awamura S, et al. Rebamipide Ophthalmic Suspension Phase 3 Study Group: A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye. Ophthalmology. 2013;120(6):1158-65.doi: 10.1016/j.ophtha.2012.12.022
Kase S, Shinohara T, Kase M. Histological observation of goblet cells following topical rebamipide treatment of the human ocular surface: A case report. Experimental and Therapeutic Medicine. 2015;9(2):456-8.doi: 10.3892/etm.2014.2108
Koh S, Inoue Y, Sugmimoto T, et al. Effect of rebamipide ophthalmic suspension on optical quality in the short break-up time type of dry eye. Cornea. 2013;32(9):1219-23. doi: 10.1097/ICO.0b013e318294f97e
Rashid S, Jin Y, Ecoiffier T, et al. Topical omega-3 and omega-6 fatty acids for treatment of dry eye. Archives of ophthalmology. 2008;126(2):219-25. doi:10.1001/archophthalmol.2007.61
Zhang Z, Yang W-Z, Zhu Z-Z, et al. Therapeutic effects of topical doxycycline in a benzalkonium chloride–induced mouse dry eye model. Investigative Ophthalmology & Visual Science. 2014;55(5):2963-74.doi: 10.1167/iovs.13-13577
Coursey TG, de Paiva CS. Managing Sjögren’s Syndrome and non-Sjögren Syndrome dry eye with anti-inflammatory therapy. Clinical Ophthalmology. 2014;8:1447. doi: 10.2147/OPTH.S35685
Walters TR, Goldberg DF, Peace JH, et al. Bromfenac ophthalmic solution 0.07% dosed once daily for cataract surgery: results of 2 randomized controlled trials. Ophthalmology. 2014;121(1):25-33.doi: 10.1016/j.ophtha.2013.07.006
Bron A, Mengher L. The ocular surface in keratoconjunctivitis sicca. Eye. 1989;3(4):428-37.doi: 10.1038/eye.1989.64
Geerling G, Hartwig D. Autologous serum-eye-drops for ocular surface disorders. A literature review and recommendations for their application. Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 2002;99(12):949-59.doi: 10.1007/s00347-002-0661-6
Pflugfelder SC, Stern M, Zhang S, et al. LFA-1/ICAM-1 interaction as a therapeutic target in dry eye disease. Journal of Ocular Pharmacology and Therapeutics. 2017;33(1):5-12.doi: 10.1089/jop.2016.0105
Balaram M, Schaumberg DA, Dana MR. Efficacy and tolerability outcomes after punctal occlusion with silicone plugs in dry eye syndrome. American Journal Of Ophthalmology. 2001;131(1):30-6.doi:: 10.1016/s0002-9394(00)00620-6
Gumus K, Schuetzle KL, Pflugfelder SC. Randomized controlled crossover trial comparing the impact of sham or intranasal tear neurostimulation on conjunctival goblet cell degranulation. American Journal Of Ophthalmology. 2017;177:159-68.doi: 10.1016/j.ajo.2017.03.002
Yu MD, Park JK, Kossler AL. Stimulating tear production: spotlight on neurostimulation. Clinical Ophthalmology. 2021:4219-26.doi: 10.2147/OPTH.S284622
Bachu RD, Chowdhury P, Al-Saedi ZH, et al. Ocular drug delivery barriers—role of nanocarriers in the treatment of anterior segment ocular diseases. Pharmaceutics. 2018;10(1):28.doi: 10.3390/pharmaceutics10010028
Natarajan JV, Darwitan A, Barathi VA, et al. Sustained drug release in nanomedicine: a long-acting nanocarrier-based formulation for glaucoma. ACS nano. 2014;8(1):419-29.doi: 10.1021/nn4046024
HS Boddu S. Polymeric nanoparticles for ophthalmic drug delivery: an update on research and patenting activity. Recent Patents On Nanomedicine. 2012;2(2):96-112.
Losa C, Marchal-Heussler L, Orallo F, et al. Design of new formulations for topical ocular administration: polymeric nanocapsules containing metipranolol. Pharmaceutical Research. 1993;10(1):80-7.doi: 10.1023/a:1018977130559
Halasz K, Kelly SJ, Iqbal MT, et al. Micro/nanoparticle delivery systems for ocular diseases. Assay and Drug Development Technologies. 2019;17(4):152-66.doi: 10.1089/adt.2018.911
Bu H-Z, Gukasyan HJ, Goulet L, et al. Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs. Current Drug Metabolism. 2007;8(2):91-107.doi: 10.2174/138920007779815977
Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Advanced Drug Delivery Reviews. 2005;57(11):1595-639.doi: 10.1016/j.addr.2005.07.005
John M, Gacche RN. Nano-formulations for ophthalmic treatments. Arch Pharm Pharma Sci. 2017;1:028-35.
Fialho SL, Da Silva‐Cunha A. New vehicle based on a microemulsion for topical ocular administration of dexamethasone. Clinical & Experimental Ophthalmology. 2004;32(6):626-32.doi: 10.1111/j.1442-9071.2004.00914.x
Vandamme TF. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Progress in retinal and eye research. 2002;21(1):15-34.doi: 10.1016/S1350-9462(01)00017-9
Coursey TG, Wassel RA, Quiambao AB, et al. Once-daily cyclosporine-A-MiDROPS for treatment of dry eye disease. Translational Vision Science & Technology. 2018;7(5):24-24 doi:10.1167/tvst.7.5.24.
Jurišić Dukovski B, Bračko A, Šare M, et al. In vitro evaluation of stearylamine cationic nanoemulsions for improved ocular drug delivery. Acta Pharmaceutica. 2019;69(4):621-34.doi: 10.2478/acph-2019-0054
Daull P, Lallemand F, Garrigue J-S. Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery. Journal Of Pharmacy And Pharmacology. 2014;66(4):531-41.doi: 10.1111/jphp.12075
Schaumberg DA, Sullivan DA, Dana MR. Epidemiology of dry eye syndrome. Lacrimal Gland, Tear Film, and Dry Eye Syndromes 3. 2002:989-98.
Lallemand F, Schmitt M, Bourges J-L, et al. Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts. European Journal of Pharmaceutics and Biopharmaceutics. 2017;117:14-28.doi: 10.1016/j.ejpb.2017.03.006
Lyseng-Williamson KA. Cationorm®(cationic emulsion eye drops) in dry eye disease: a guide to its use. Drugs & Therapy Perspectives. 2016;32(8):317-22.
Ahmadi Tehrani A, Omranpoor MM, Vatanara A, et al. Formation of nanosuspensions in bottom-up approach: theories and optimization. DARU Journal of Pharmaceutical Sciences. 2019;27(1):451-73.doi: 10.1007/s40199-018-00235-2
Luschmann C, Tessmar J, Schoeberl S, et al. Developing an in situ nanosuspension: A novel approach towards the efficient administration of poorly soluble drugs at the anterior eye. European Journal of Pharmaceutical Sciences. 2013;50(3-4):385-92.doi: 10.1016/j.ejps.2013.07.002
Kim JH, Jang SW, Han SD, et al. Development of a novel ophthalmic ciclosporin A-loaded nanosuspension using top-down media milling methods. Die Pharmazie-An International Journal of Pharmaceutical Sciences. 2011;66(7):491-5.doi: 10.1691/ph.2011.0358
Akhgari A, Saremi H, Khodayar MJ. Preparation and evaluation of vitamin A nanosuspension as a novel ocular drug delivery. Nanomedicine Journal. 2015;2(4):283-90.
Kaur IP, Garg A, Singla AK, et al. Vesicular systems in ocular drug delivery: an overview. International Journal Of Pharmaceutics. 2004;269(1):1-14.doi: 10.1016/j.ijpharm.2003.09.016
McCann LC, Tomlinson A, Pearce EI, et al. Effectiveness of artificial tears in the management of evaporative dry eye. Cornea. 2012;31(1):1-5. doi: 10.1097/ICO.0b013e31821b71e6
Linares-Alba MA, Gómez-Guajardo MB, Fonzar JF, et al. Preformulation studies of a liposomal formulation containing sirolimus for the treatment of dry eye disease. Journal of Ocular Pharmacology and Therapeutics. 2016;32(1):11-22.doi: 10.1089/jop.2015.0032
Tawfik SM, Azizov S, Elmasry MR, et al. Recent advances in nanomicelles delivery systems. Nanomaterials. 2020;11(1):70.doi: 10.3390/nano11010070
Deshmukh AS, Chauhan PN, Noolvi MN, et al. Polymeric micelles: Basic research to clinical practice. International Journal Of Pharmaceutics. 2017;532(1):249-68.doi: 10.1016/j.ijpharm.2017.09.005
Cholkar K, Patel A, Dutt Vadlapudi A, et al. Novel nanomicellar formulation approaches for anterior and posterior segment ocular drug delivery. Recent Patents On Nanomedicine. 2012;2(2):82-95.doi: 10.2174/1877912311202020082
Tsinman O, Tsinman K, Ali S. Excipient update-Soluplus®: An understanding of supersaturation from amorphous solid dispersions. Drug Delivery Technology. 2015;15(1).
Di Tommaso C, Valamanesh F, Miller F, et al. A novel cyclosporin a aqueous formulation for dry eye treatment: in vitro and in vivo evaluation. Investigative Ophthalmology & Visual Science. 2012;53(4):2292-9.doi: 10.1167/iovs.11-8829
Guo C, Zhang Y, Yang Z, et al. Nanomicelle formulation for topical delivery of cyclosporine A into the cornea: in vitro mechanism and in vivo permeation evaluation. Scientific Reports. 2015;5(1):1-14.
Mandal A, Bisht R, Rupenthal ID, et al. Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies. Journal of Controlled Release. 2017;248:96-116.doi: 10.1016/j.jconrel.2017.01.012
Shen Y, Yu Y, Chaurasiya B, et al. Stability, safety, and transcorneal mechanistic studies of ophthalmic lyophilized cyclosporine-loaded polymeric micelles. International Journal Of Nanomedicine. 2018;13:8281. doi: 10.2147/IJN.S173691
Kang H, Cha K-H, Cho W, et al. Cyclosporine Amicellar delivery system for dry eyes. International Journal Of Nanomedicine. 2016;11:2921. doi: 10.2147/IJN.S107569
Shah M, Edman MC, Janga SR, et al. Rapamycin eye drops suppress lacrimal gland inflammation in a murine model of Sjögren's syndrome. Investigative Ophthalmology & Visual Science. 2017;58(1):372-85.doi: 10.1167/iovs.16-19159
Cholkar K, Gilger BC, Mitra AK. Topical, aqueous, clear cyclosporine formulation design for anterior and posterior ocular delivery. Translational Vision Science & Technology. 2015;4(3):1-1.doi: 10.1167/tvst.4.3.1
Sawant KK, Dodiya SS. Recent advances and patents on solid lipid nanoparticles. Recent Patents On Drug Delivery & Formulation. 2008;2(2):120-35.doi: 10.2174/187221108784534081
Polat HK, Kurt N, Aytekin E, et al. Design of Besifloxacin HCl-Loaded Nanostructured Lipid Carriers: In Vitro and Ex Vivo Evaluation. Journal of Ocular Pharmacology and Therapeutics. 2022.doi: 10.1089/jop.2022.0008
Khan S, Baboota S, Ali J, et al. Nanostructured lipid carriers: an emerging platform for improving oral bioavailability of lipophilic drugs. International Journal Of Pharmaceutical Investigation. 2015;5(4):182. doi: 10.4103/2230-973X.167661
Shen J, Wang Y, Ping Q, et al. Mucoadhesive effect of thiolated PEG stearate and its modified NLC for ocular drug delivery. Journal Of Controlled Release. 2009;137(3):217-23.doi: 10.1016/j.jconrel.2009.04.021
Shen J, Deng Y, Jin X, et al. Thiolated nanostructured lipid carriers as a potential ocular drug delivery system for cyclosporine A: Improving in vivo ocular distribution. International Journal Of Pharmaceutics. 2010;402(1-2):248-53.doi: 10.1016/j.ijpharm.2010.10.008
Niamprem P, Teapavarapruk P, Srinivas SP, et al. Impact of nanostructured lipid carriers as an artificial tear film in a rabbit evaporative dry eye model. Cornea. 2019;38(4):485-91. doi: 10.1097/ICO.0000000000001867
Richichi B, Baldoneschi V, Burgalassi S, et al. A divalent PAMAM‐based matrix metalloproteinase/carbonic anhydrase inhibitor for the treatment of dry eye syndrome. Chemistry–A European Journal. 2016;22(5):1714-21.doi: 10.1002/chem.201504355
Lin H, Liu Y, Kambhampati SP, et al. Subconjunctival dendrimer-drug therapy for the treatment of dry eye in a rabbit model of induced autoimmune dacryoadenitis. The Ocular Surface. 2018;16(4):415-23.doi: 10.1016/j.jtos.2018.05.004
Lancina III MG, Yang H. Dendrimers for ocular drug delivery. Canadian Journal Of Chemistry. 2017;95(9):897-902.doi: 10.1139/cjc-2017-0193
Yuan X, Marcano DC, Shin CS, et al. Ocular drug delivery nanowafer with enhanced therapeutic efficacy. ACS Nano. 2015;9(2):1749-58.doi: 10.1021/nn506599f
Mehra NK, Cai D, Kuo L, et al. Safety and toxicity of nanomaterials for ocular drug delivery applications. Nanotoxicology. 2016;10(7):836-60.doi: 10.3109/17435390.2016.1153165
Coursey TG, Henriksson JT, Marcano DC, et al. Dexamethasone nanowafer as an effective therapy for dry eye disease. Journal of Controlled Release. 2015;213:168-74.doi: 10.1016/j.jconrel.2015.07.007
Park BC, Kim HT, Koh JW. New Biodegradable Drug Delivery System for Patients with Dry Eye. Korean Journal of Ophthalmology: KJO. 2021;35(6):455. doi: 10.3341/kjo.2021.0126
Mahmoudi A, Malaekeh-Nikouei B, Hanafi-Bojd MY, et al. Preliminary in vivo safety evaluation of a tacrolimus eye drop formulation using hydroxypropyl beta cyclodextrin after ocular administration in NZW rabbits. Clinical Ophthalmology (Auckland, NZ). 2020;14:947. doi: 10.2147/OPTH.S229405
Gupta PK, Venkateswaran N. The role of KPI-121 0.25% in the treatment of dry eye disease: penetrating the mucus barrier to treat periodic flares. Therapeutic Advances in Ophthalmology. 2021;13:25158414211012797.
